Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)

Vertex Pharmaceuticals dominates the cystic fibrosis (CF) drug market with a near-monopoly u2014 its Trikafta/Kaftrio treatment is used by roughly 90% of CF patients who are eligible. The company has expanded into pain (non-opioid treatments), sickle cell disease (Casgevy, the first CRISPR-based gene therapy), and kidney disease. Vertex is one of the most consistently innovative biotech companies, with a pipeline that extends well beyond CF.

CF drug sales (Trikafta, Orkambi, Symdeko) account for virtually all revenue, which exceeds $9.8 billion annually. Trikafta alone generates over $8 billion. The company is investing in diversification u2014 Casgevy (gene therapy for sickle cell, co-developed with CRISPR Therapeutics) and a non-opioid pain drug (suzetrigine) represent the next growth chapters. R&D spending exceeds $3 billion annually.

Joshua Boger founded Vertex in Cambridge, Massachusetts in 1989. The company initially focused on HIV and hepatitis C before pivoting to cystic fibrosis. Kalydeco, the first CF drug, launched in 2012. Trikafta's approval in 2019 was transformative u2014 it treats the underlying cause of CF, not just symptoms. Casgevy received FDA approval in 2023 as the first CRISPR gene therapy ever approved.